• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

would anybody really care or notice is Eisai disappeared tomorrow?


<